 Carol Sartorius
Concepts (312)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 49 | 2022 | 1965 | 6.370 |
Why?
| | Receptors, Progesterone | 34 | 2020 | 325 | 5.730 |
Why?
| | Progesterone | 14 | 2021 | 242 | 3.960 |
Why?
| | Keratin-5 | 9 | 2022 | 47 | 3.670 |
Why?
| | Receptors, Estrogen | 25 | 2022 | 387 | 3.040 |
Why?
| | Progestins | 12 | 2021 | 77 | 2.800 |
Why?
| | Neoplastic Stem Cells | 12 | 2020 | 336 | 2.580 |
Why?
| | Estrogens | 9 | 2018 | 328 | 1.800 |
Why?
| | Cell Line, Tumor | 24 | 2021 | 2851 | 1.390 |
Why?
| | Estrogen Receptor alpha | 5 | 2022 | 126 | 1.300 |
Why?
| | Receptors, Androgen | 5 | 2021 | 134 | 0.990 |
Why?
| | Gene Expression Regulation, Neoplastic | 15 | 2022 | 1167 | 0.930 |
Why?
| | Xenograft Model Antitumor Assays | 10 | 2020 | 740 | 0.890 |
Why?
| | Keratin-17 | 1 | 2022 | 4 | 0.890 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2020 | 671 | 0.830 |
Why?
| | Estradiol | 8 | 2016 | 476 | 0.820 |
Why?
| | Biomarkers, Tumor | 8 | 2022 | 1059 | 0.800 |
Why?
| | Mammary Glands, Animal | 3 | 2012 | 124 | 0.770 |
Why?
| | Carcinoma, Lobular | 1 | 2020 | 56 | 0.720 |
Why?
| | Cell Proliferation | 14 | 2021 | 2275 | 0.710 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2020 | 91 | 0.710 |
Why?
| | Receptor, ErbB-2 | 4 | 2020 | 320 | 0.690 |
Why?
| | Mice | 33 | 2020 | 15520 | 0.650 |
Why?
| | beta Catenin | 1 | 2020 | 219 | 0.630 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2017 | 11 | 0.620 |
Why?
| | Antineoplastic Agents, Hormonal | 9 | 2020 | 143 | 0.610 |
Why?
| | RNA Polymerase III | 1 | 2017 | 25 | 0.610 |
Why?
| | Receptors, Retinoic Acid | 1 | 2017 | 41 | 0.610 |
Why?
| | Female | 50 | 2022 | 61565 | 0.600 |
Why?
| | Tamoxifen | 7 | 2020 | 198 | 0.590 |
Why?
| | Stem Cells | 2 | 2011 | 559 | 0.570 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2015 | 164 | 0.560 |
Why?
| | MicroRNAs | 4 | 2015 | 637 | 0.550 |
Why?
| | Tumor Suppressor Proteins | 2 | 2015 | 289 | 0.540 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 41 | 0.530 |
Why?
| | Mice, SCID | 6 | 2020 | 333 | 0.530 |
Why?
| | Paracrine Communication | 1 | 2015 | 57 | 0.530 |
Why?
| | Neoplasms, Hormone-Dependent | 2 | 2012 | 38 | 0.500 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 43 | 0.500 |
Why?
| | Cisplatin | 1 | 2015 | 271 | 0.490 |
Why?
| | Tumor Microenvironment | 7 | 2021 | 454 | 0.480 |
Why?
| | Astrocytes | 1 | 2015 | 177 | 0.470 |
Why?
| | Animals | 37 | 2020 | 33381 | 0.470 |
Why?
| | Humans | 63 | 2023 | 118974 | 0.470 |
Why?
| | Signal Transduction | 9 | 2021 | 4709 | 0.470 |
Why?
| | Mice, Inbred NOD | 5 | 2020 | 574 | 0.460 |
Why?
| | Tumor Cells, Cultured | 10 | 2020 | 874 | 0.450 |
Why?
| | Gene Expression Profiling | 13 | 2020 | 1597 | 0.450 |
Why?
| | Ovarian Neoplasms | 2 | 2015 | 420 | 0.450 |
Why?
| | Transcriptome | 4 | 2020 | 756 | 0.430 |
Why?
| | Heterografts | 5 | 2020 | 130 | 0.430 |
Why?
| | Medroxyprogesterone Acetate | 2 | 2015 | 30 | 0.410 |
Why?
| | Mammary Glands, Human | 1 | 2011 | 61 | 0.400 |
Why?
| | Hyaluronan Receptors | 6 | 2014 | 93 | 0.380 |
Why?
| | Carcinogenesis | 2 | 2020 | 182 | 0.330 |
Why?
| | MCF-7 Cells | 6 | 2021 | 111 | 0.320 |
Why?
| | Estrogen Replacement Therapy | 1 | 2008 | 117 | 0.310 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1022 | 0.300 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 1974 | 0.300 |
Why?
| | Androgens | 2 | 2021 | 167 | 0.290 |
Why?
| | Mice, Nude | 6 | 2015 | 663 | 0.280 |
Why?
| | Lymphatic Metastasis | 5 | 2017 | 307 | 0.270 |
Why?
| | Transplantation, Heterologous | 6 | 2016 | 194 | 0.270 |
Why?
| | Antigens, CD | 2 | 2020 | 460 | 0.260 |
Why?
| | DNA-Binding Proteins | 3 | 2015 | 1346 | 0.260 |
Why?
| | Models, Theoretical | 1 | 2008 | 556 | 0.240 |
Why?
| | Promoter Regions, Genetic | 5 | 2017 | 1158 | 0.240 |
Why?
| | Apoptosis | 6 | 2017 | 2484 | 0.240 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2016 | 317 | 0.240 |
Why?
| | Pharmacology, Clinical | 1 | 2023 | 8 | 0.240 |
Why?
| | Myosin Heavy Chains | 3 | 2001 | 192 | 0.230 |
Why?
| | Cyclic AMP | 3 | 1995 | 242 | 0.230 |
Why?
| | Down-Regulation | 3 | 2015 | 627 | 0.230 |
Why?
| | Nuclear Proteins | 2 | 2015 | 597 | 0.230 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2020 | 63 | 0.220 |
Why?
| | Neoplasm Transplantation | 3 | 2016 | 245 | 0.220 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2008 | 900 | 0.220 |
Why?
| | Homeodomain Proteins | 3 | 2018 | 468 | 0.220 |
Why?
| | Disease Progression | 5 | 2021 | 2490 | 0.220 |
Why?
| | Vimentin | 1 | 2022 | 62 | 0.220 |
Why?
| | Gene Knockout Techniques | 2 | 2020 | 105 | 0.210 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 28 | 0.210 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2015 | 455 | 0.200 |
Why?
| | Cell Division | 1 | 2003 | 776 | 0.200 |
Why?
| | Doxorubicin | 1 | 2022 | 302 | 0.200 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2020 | 58 | 0.190 |
Why?
| | Transcription Factors | 5 | 2023 | 1570 | 0.190 |
Why?
| | Leukocytes, Mononuclear | 2 | 2020 | 509 | 0.190 |
Why?
| | Thyroid Hormones | 1 | 2020 | 55 | 0.190 |
Why?
| | Transcription, Genetic | 6 | 2020 | 1323 | 0.190 |
Why?
| | Neoplasm Metastasis | 2 | 2020 | 544 | 0.190 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 18 | 0.190 |
Why?
| | Saccharomyces cerevisiae Proteins | 2 | 2001 | 348 | 0.180 |
Why?
| | Adherens Junctions | 1 | 2020 | 26 | 0.180 |
Why?
| | Protein Isoforms | 3 | 2019 | 345 | 0.180 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 62 | 0.180 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 87 | 0.180 |
Why?
| | Hormone Replacement Therapy | 1 | 2020 | 80 | 0.180 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 462 | 0.180 |
Why?
| | Immunoprecipitation | 1 | 2020 | 161 | 0.180 |
Why?
| | Forkhead Box Protein O1 | 1 | 2019 | 15 | 0.180 |
Why?
| | Cluster Analysis | 4 | 2019 | 481 | 0.170 |
Why?
| | Protein Interaction Mapping | 1 | 2020 | 104 | 0.170 |
Why?
| | Up-Regulation | 2 | 2020 | 872 | 0.170 |
Why?
| | DNA Helicases | 1 | 2000 | 131 | 0.170 |
Why?
| | Tretinoin | 2 | 2017 | 116 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 176 | 0.170 |
Why?
| | Disease Susceptibility | 1 | 2021 | 331 | 0.170 |
Why?
| | Cadherins | 1 | 2020 | 186 | 0.170 |
Why?
| | Lipid Metabolism | 1 | 2021 | 477 | 0.160 |
Why?
| | Mass Spectrometry | 2 | 2020 | 681 | 0.160 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 150 | 0.160 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 52 | 0.160 |
Why?
| | Risk | 1 | 2021 | 853 | 0.160 |
Why?
| | Lipids | 1 | 2021 | 607 | 0.160 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 356 | 0.160 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 187 | 0.150 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 2 | 1994 | 17 | 0.150 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 14 | 0.150 |
Why?
| | Glucose Transporter Type 1 | 1 | 2016 | 42 | 0.150 |
Why?
| | Phenylthiohydantoin | 1 | 2016 | 40 | 0.140 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 409 | 0.140 |
Why?
| | Disease Models, Animal | 4 | 2016 | 3730 | 0.140 |
Why?
| | ErbB Receptors | 2 | 2020 | 569 | 0.140 |
Why?
| | Cell Membrane | 1 | 2020 | 710 | 0.140 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 52 | 0.140 |
Why?
| | Ribosomal Proteins | 1 | 2015 | 68 | 0.130 |
Why?
| | CD146 Antigen | 3 | 2021 | 41 | 0.130 |
Why?
| | Transcriptional Activation | 3 | 2006 | 348 | 0.130 |
Why?
| | Mutation | 4 | 2022 | 3457 | 0.130 |
Why?
| | Azepines | 1 | 2015 | 74 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2019 | 527 | 0.130 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 311 | 0.120 |
Why?
| | Binding Sites | 6 | 2016 | 1224 | 0.120 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 333 | 0.120 |
Why?
| | Phenotype | 4 | 2011 | 3003 | 0.120 |
Why?
| | Molecular Sequence Data | 7 | 2012 | 2871 | 0.120 |
Why?
| | Endometrial Neoplasms | 1 | 2015 | 144 | 0.120 |
Why?
| | Glycoproteins | 1 | 2015 | 319 | 0.120 |
Why?
| | Muscle, Skeletal | 3 | 2001 | 1515 | 0.110 |
Why?
| | Ligands | 3 | 2023 | 567 | 0.110 |
Why?
| | RNA, Messenger | 2 | 2019 | 2657 | 0.110 |
Why?
| | Immunohistochemistry | 2 | 2015 | 1691 | 0.110 |
Why?
| | Peptide Fragments | 3 | 2003 | 702 | 0.110 |
Why?
| | Gene Regulatory Networks | 2 | 2012 | 239 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 770 | 0.110 |
Why?
| | CD24 Antigen | 1 | 2012 | 21 | 0.110 |
Why?
| | Chromatin | 1 | 2016 | 441 | 0.110 |
Why?
| | Mifepristone | 3 | 2020 | 65 | 0.110 |
Why?
| | Retinoids | 1 | 2012 | 32 | 0.110 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 31 | 0.110 |
Why?
| | Cell Survival | 1 | 2015 | 1047 | 0.110 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 56 | 0.110 |
Why?
| | Pyrimidines | 1 | 2015 | 382 | 0.100 |
Why?
| | Cell Differentiation | 2 | 2012 | 1753 | 0.100 |
Why?
| | Small Molecule Libraries | 1 | 2012 | 80 | 0.100 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 160 | 0.100 |
Why?
| | Tumor Burden | 1 | 2012 | 274 | 0.100 |
Why?
| | Drug Discovery | 1 | 2012 | 124 | 0.100 |
Why?
| | Cell Movement | 1 | 2015 | 896 | 0.100 |
Why?
| | Receptors, Notch | 1 | 2011 | 85 | 0.100 |
Why?
| | HeLa Cells | 4 | 2006 | 583 | 0.100 |
Why?
| | Cell Size | 1 | 2010 | 86 | 0.090 |
Why?
| | Peritoneal Neoplasms | 1 | 2010 | 53 | 0.090 |
Why?
| | HEK293 Cells | 1 | 2012 | 625 | 0.090 |
Why?
| | Peptides | 1 | 2015 | 879 | 0.090 |
Why?
| | Ovariectomy | 1 | 2010 | 124 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 462 | 0.090 |
Why?
| | Cell Growth Processes | 2 | 2006 | 54 | 0.090 |
Why?
| | Adenocarcinoma | 1 | 2015 | 812 | 0.090 |
Why?
| | Flow Cytometry | 1 | 2012 | 1085 | 0.090 |
Why?
| | Embryonal Carcinoma Stem Cells | 1 | 2008 | 2 | 0.080 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2001 | 192 | 0.080 |
Why?
| | Neoplasms, Experimental | 1 | 2008 | 158 | 0.080 |
Why?
| | Phosphorylation | 3 | 2008 | 1633 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 842 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2019 | 2220 | 0.070 |
Why?
| | Histone Acetyltransferases | 1 | 2006 | 53 | 0.070 |
Why?
| | Keratins | 1 | 2005 | 174 | 0.070 |
Why?
| | Obesity | 1 | 2018 | 2746 | 0.070 |
Why?
| | Amino Acid Sequence | 3 | 2012 | 2071 | 0.060 |
Why?
| | Organ Specificity | 2 | 2010 | 278 | 0.060 |
Why?
| | Chloramphenicol O-Acetyltransferase | 2 | 1994 | 37 | 0.060 |
Why?
| | Gonanes | 2 | 1994 | 28 | 0.060 |
Why?
| | Models, Biological | 2 | 2008 | 1715 | 0.060 |
Why?
| | Lymph Nodes | 1 | 2006 | 455 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2020 | 2025 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2020 | 2680 | 0.060 |
Why?
| | Genes, Reporter | 2 | 2012 | 270 | 0.060 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2022 | 11 | 0.060 |
Why?
| | Base Sequence | 3 | 2001 | 2159 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2005 | 401 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2022 | 2445 | 0.050 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 195 | 0.050 |
Why?
| | Aromatase Inhibitors | 1 | 2021 | 52 | 0.050 |
Why?
| | Neoplasms | 1 | 2015 | 2179 | 0.050 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2021 | 6 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 32 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 37 | 0.050 |
Why?
| | Nucleosomes | 1 | 2022 | 131 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2021 | 180 | 0.050 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2000 | 10 | 0.050 |
Why?
| | Ku Autoantigen | 1 | 2000 | 12 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2021 | 228 | 0.050 |
Why?
| | Glutathione Transferase | 1 | 2000 | 97 | 0.050 |
Why?
| | Cell Nucleus | 2 | 2016 | 580 | 0.040 |
Why?
| | Methionine | 1 | 2000 | 145 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 144 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 726 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 339 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2020 | 649 | 0.040 |
Why?
| | Prognosis | 2 | 2020 | 3443 | 0.040 |
Why?
| | Gene Library | 1 | 2019 | 127 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 103 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2020 | 313 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2019 | 268 | 0.040 |
Why?
| | Adult | 2 | 2017 | 31512 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2018 | 42 | 0.040 |
Why?
| | Breast | 1 | 2019 | 140 | 0.040 |
Why?
| | Diaphragm | 1 | 1998 | 36 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2012 | 372 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2000 | 397 | 0.040 |
Why?
| | Myosins | 1 | 1998 | 130 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1206 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2001 | 363 | 0.040 |
Why?
| | Heterozygote | 1 | 1998 | 262 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2020 | 442 | 0.040 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 823 | 0.040 |
Why?
| | Autoantigens | 1 | 2000 | 397 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 653 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2001 | 502 | 0.040 |
Why?
| | Cyclohexanes | 1 | 2016 | 22 | 0.040 |
Why?
| | Transfection | 2 | 2003 | 888 | 0.040 |
Why?
| | Transduction, Genetic | 1 | 2016 | 116 | 0.040 |
Why?
| | Luminescent Measurements | 1 | 2016 | 72 | 0.040 |
Why?
| | Anilides | 1 | 2016 | 69 | 0.040 |
Why?
| | AC133 Antigen | 1 | 2015 | 20 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 453 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 155 | 0.030 |
Why?
| | Benzamides | 1 | 2016 | 176 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2003 | 1308 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 65 | 0.030 |
Why?
| | Tumor Protein p73 | 1 | 2015 | 15 | 0.030 |
Why?
| | Fibroblasts | 1 | 2020 | 842 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 315 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 1012 | 0.030 |
Why?
| | Aurora Kinase A | 1 | 2015 | 52 | 0.030 |
Why?
| | Hormone Antagonists | 1 | 1995 | 41 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 493 | 0.030 |
Why?
| | TATA Box | 1 | 1994 | 24 | 0.030 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 1994 | 41 | 0.030 |
Why?
| | Software | 1 | 2019 | 613 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 606 | 0.030 |
Why?
| | Drug Synergism | 1 | 1994 | 339 | 0.030 |
Why?
| | Amino Acid Motifs | 2 | 2006 | 200 | 0.030 |
Why?
| | Promegestone | 1 | 1993 | 33 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 1993 | 65 | 0.030 |
Why?
| | Wolves | 1 | 2012 | 1 | 0.030 |
Why?
| | Raccoon Dogs | 1 | 2012 | 1 | 0.030 |
Why?
| | Foxes | 1 | 2012 | 3 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1993 | 139 | 0.030 |
Why?
| | Acitretin | 1 | 2012 | 3 | 0.030 |
Why?
| | Miconazole | 1 | 2012 | 4 | 0.030 |
Why?
| | Cell Line | 2 | 2001 | 2707 | 0.030 |
Why?
| | Isotretinoin | 1 | 2012 | 22 | 0.030 |
Why?
| | CHO Cells | 1 | 2012 | 143 | 0.030 |
Why?
| | DNA | 2 | 2001 | 1388 | 0.030 |
Why?
| | Cricetinae | 1 | 2012 | 262 | 0.030 |
Why?
| | Phosphates | 1 | 1993 | 167 | 0.030 |
Why?
| | Luciferases | 1 | 2012 | 143 | 0.030 |
Why?
| | Male | 3 | 2016 | 57801 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 142 | 0.030 |
Why?
| | Claudins | 1 | 2011 | 24 | 0.030 |
Why?
| | Dogs | 1 | 2012 | 371 | 0.030 |
Why?
| | Glucose | 1 | 2016 | 953 | 0.030 |
Why?
| | Species Specificity | 1 | 2012 | 565 | 0.020 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2011 | 76 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2010 | 26 | 0.020 |
Why?
| | Diet | 1 | 2018 | 1153 | 0.020 |
Why?
| | Liver | 1 | 2019 | 1816 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 395 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5116 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 195 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2012 | 408 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 811 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 982 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2008 | 15 | 0.020 |
Why?
| | Microdissection | 1 | 2007 | 13 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1194 | 0.020 |
Why?
| | Lasers | 1 | 2007 | 124 | 0.020 |
Why?
| | Nuclear Receptor Coactivator 1 | 1 | 2006 | 10 | 0.020 |
Why?
| | Lung | 1 | 2019 | 3664 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2006 | 100 | 0.020 |
Why?
| | Protein Kinases | 1 | 2008 | 310 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 338 | 0.020 |
Why?
| | COS Cells | 1 | 2003 | 184 | 0.010 |
Why?
| | Mutagenesis | 1 | 2003 | 176 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2003 | 336 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1293 | 0.010 |
Why?
| | Uterus | 1 | 2003 | 194 | 0.010 |
Why?
| | Sequence Deletion | 1 | 2001 | 171 | 0.010 |
Why?
| | Hypertrophy | 1 | 2001 | 121 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2001 | 152 | 0.010 |
Why?
| | Protein Binding | 1 | 2006 | 1975 | 0.010 |
Why?
| | Organ Size | 1 | 2001 | 460 | 0.010 |
Why?
| | Reference Values | 1 | 2001 | 774 | 0.010 |
Why?
| | Aged | 1 | 2015 | 19657 | 0.010 |
Why?
| | Body Weight | 1 | 2001 | 934 | 0.010 |
Why?
| | Motor Activity | 1 | 2001 | 660 | 0.010 |
Why?
| | Middle Aged | 1 | 2015 | 27617 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2001 | 601 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2001 | 1055 | 0.010 |
Why?
|
|
Sartorius's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|